- 2,3-dihydrophthalazine-1,4-diones
-
A compound having the structural formula STR1 wherein R1 is hydrogen, C1 -C6 alkyl, C2 -C6 carbalkoxyalkyl or phenyl substituted with C1 -C3 alkyl or halogen; R2 is hydrogen or C1 -C6 alkyl; and R3 and R4 are the same or different and are hydrogen, C1 -C3 alkyl, C1 -C3 alkoxy or halogen with the provisos that if R2, R3 and R4 are hydrogen, then R1 is not methyl, n-propyl or phenyl substituted with methyl in the ortho or para position; if R1, R2 and R3 are hydrogen then R4 is not hydrogen, methyl or methoxy; and if R1 and R2 are both n-propyl or n-butyl then R3 and R4 are not both hydrogen. These compounds demonstrate utility as hypolipidemic agents. The present invention is also directed to a process for controlling hyperlipidemia in mammals comprising treating mammals with a hyperlipidemia controlling effective amount of a compound having the above-identified structural formula wherein R1 is hydrogen, C1 -C6 alkyl, C2 -C6 carboxyalkyl, C2 -C6 carbalkoxyalkyl, phenyl or phenyl substituted with C1 -C3 alkyl or halogen; R2 is hydrogen or C1 -C6 alkyl; and R3 and R4 are the same or different and are hydrogen, C1 -C3 alkyl, C1 -C3 alkoxy or halogen. Yet another aspect of the present invention is embodied in a pharmaceutical composition comprising a compound having the above structural formula wherein R1 is hydrogen, C1 -C6 alkyl, C2 -C6 carboxyalkyl, C2 -C6 carbalkoxyalkyl, phenyl or phenyl substituted with C1 -C3 alkyl or halogen; R2 is hydrogen or C1 -C6 alkyl; and R3 and R4 are the same or different and are hydrogen, C1 -C3 alkyl, C1 -C3 alkoxy or halogen and a pharmaceutically acceptable carrier therefor.
- -
-
-